atrasentan has been researched along with Cancer of Kidney in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carducci, MA; Dutcher, JP; Liu, G; Manola, J; Nair, SG; Rousey, S; Wilding, G | 1 |
| de Gast, B; Giles, R; Groenewegen, G; Haanen, J; Vermaat, J; Voest, E; Walraven, M; Witteveen, E | 1 |
2 trial(s) available for atrasentan and Cancer of Kidney
| Article | Year |
|---|---|
Atrasentan in Patients With Advanced Renal Cell Carcinoma: A Phase 2 Trial of the ECOG-ACRIN Cancer Research Group (E6800).
Topics: Adult; Aged; Aged, 80 and over; Atrasentan; Bone Neoplasms; Carcinoma, Renal Cell; Disease-Free Survival; Endothelin Receptor Antagonists; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Pyrrolidines; Treatment Outcome | 2015 |
Targeting the endothelin axis with atrasentan, in combination with IFN-alpha, in metastatic renal cell carcinoma.
Topics: Adult; Aged; Atrasentan; Carcinoma, Renal Cell; Cohort Studies; Drug Therapy, Combination; Endothelins; Female; Humans; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrrolidines | 2012 |